Roche Wins Funding For Second Histology-Independent Drug In England
Executive Summary
Patients in England with NTRK fusion-positive solid tumors will now have access to another cutting-edge cancer treatment that can be used to treat tumors regardless of where in the body they originated.
You may also be interested in...
English Funding Success For Roche’s Rozlytrek In NSCLC
English patients with advanced NSCLC now have another NHS treatment option in the form of Roche’s entrectinib.
English Funding Success For Roche’s Rozlytrek In NSCLC
English patients with advanced NSCLC now have another NHS treatment option in the form of Roche’s entrectinib.
EU Approvals In Sight For Novartis, Roche, and Janssen
EU approval is a formality for the eight products given the nod this week at the European Medicines Agency. There's no word, though, on filgotimid, from Gilead/Galapagos.